Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Correction: Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.

Bjoern J, Lyngaa R, Andersen R, Hölmich LR, Hadrup SR, Donia M, Svane IM.

Oncotarget. 2018 Nov 9;9(88):35870. doi: 10.18632/oncotarget.26359. eCollection 2018 Nov 9.

2.

T cell receptor fingerprinting enables in-depth characterization of the interactions governing recognition of peptide-MHC complexes.

Bentzen AK, Such L, Jensen KK, Marquard AM, Jessen LE, Miller NJ, Church CD, Lyngaa R, Koelle DM, Becker JC, Linnemann C, Schumacher TNM, Marcatili P, Nghiem P, Nielsen M, Hadrup SR.

Nat Biotechnol. 2018 Nov 19. doi: 10.1038/nbt.4303. [Epub ahead of print]

PMID:
30451992
3.

Prediction of neoepitopes from murine sequencing data.

Bjerregaard AM, Pedersen TK, Marquard AM, Hadrup SR.

Cancer Immunol Immunother. 2018 Oct 5. doi: 10.1007/s00262-018-2254-5. [Epub ahead of print] No abstract available.

PMID:
30291365
4.

Human endogenous retroviruses and their implication for immunotherapeutics of cancer.

Attermann AS, Bjerregaard AM, Saini SK, Grønbæk K, Hadrup SR.

Ann Oncol. 2018 Nov 1;29(11):2183-2191. doi: 10.1093/annonc/mdy413.

PMID:
30239576
5.

Corrigendum: An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes.

Bjerregaard AM, Nielsen M, Jurtz V, Barra CM, Hadrup SR, Szallasi Z, Eklund AC.

Front Immunol. 2018 May 14;9:1007. doi: 10.3389/fimmu.2018.01007. eCollection 2018.

6.

Development of an RNA-based kit for easy generation of TCR-engineered lymphocytes to control T-cell assay performance.

Bidmon N, Kind S, Welters MJP, Joseph-Pietras D, Laske K, Maurer D, Hadrup SR, Schreibelt G, Rae R, Sahin U, Gouttefangeas C, Britten CM, van der Burg SH.

J Immunol Methods. 2018 Jul;458:74-82. doi: 10.1016/j.jim.2018.04.007. Epub 2018 Apr 21.

7.

T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.

Andersen R, Westergaard MCW, Kjeldsen JW, Müller A, Pedersen NW, Hadrup SR, Met Ö, Seliger B, Kromann-Andersen B, Hasselager T, Donia M, Svane IM.

Cancer Immunol Res. 2018 Feb;6(2):222-235. doi: 10.1158/2326-6066.CIR-17-0467. Epub 2018 Jan 4.

PMID:
29301752
8.

An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes.

Bjerregaard AM, Nielsen M, Jurtz V, Barra CM, Hadrup SR, Szallasi Z, Eklund AC.

Front Immunol. 2017 Nov 15;8:1566. doi: 10.3389/fimmu.2017.01566. eCollection 2017. Erratum in: Front Immunol. 2018 May 14;9:1007.

9.

Novel tools to assist neoepitope targeting in personalized cancer immunotherapy.

Saini SK, Rekers N, Hadrup SR.

Ann Oncol. 2017 Dec 1;28(suppl_12):xii3-xii10. doi: 10.1093/annonc/mdx544. Review.

PMID:
29092006
10.

Automated Analysis of Flow Cytometry Data to Reduce Inter-Lab Variation in the Detection of Major Histocompatibility Complex Multimer-Binding T Cells.

Pedersen NW, Chandran PA, Qian Y, Rebhahn J, Petersen NV, Hoff MD, White S, Lee AJ, Stanton R, Halgreen C, Jakobsen K, Mosmann T, Gouttefangeas C, Chan C, Scheuermann RH, Hadrup SR.

Front Immunol. 2017 Jul 26;8:858. doi: 10.3389/fimmu.2017.00858. eCollection 2017.

11.

Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination.

Gerer KF, Erdmann M, Hadrup SR, Lyngaa R, Martin LM, Voll RE, Schuler-Thurner B, Schuler G, Schaft N, Hoyer S, Dörrie J.

Ther Adv Med Oncol. 2017 Jul;9(7):451-464. doi: 10.1177/1758834017712630. Epub 2017 Jun 13.

12.

PD-1+ Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer.

Donia M, Kjeldsen JW, Andersen R, Westergaard MCW, Bianchi V, Legut M, Attaf M, Szomolay B, Ott S, Dolton G, Lyngaa R, Hadrup SR, Sewell AK, Svane IM.

Clin Cancer Res. 2017 Oct 1;23(19):5779-5788. doi: 10.1158/1078-0432.CCR-16-1692. Epub 2017 Jul 5.

13.

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.

Donia M, Harbst K, van Buuren M, Kvistborg P, Lindberg MF, Andersen R, Idorn M, Munir Ahmad S, Ellebæk E, Mueller A, Fagone P, Nicoletti F, Libra M, Lauss M, Hadrup SR, Schmidt H, Andersen MH, Thor Straten P, Nilsson JA, Schumacher TN, Seliger B, Jönsson G, Svane IM.

Cancer Res. 2017 Sep 1;77(17):4562-4566. doi: 10.1158/0008-5472.CAN-16-3172. Epub 2017 Jun 27.

14.

MuPeXI: prediction of neo-epitopes from tumor sequencing data.

Bjerregaard AM, Nielsen M, Hadrup SR, Szallasi Z, Eklund AC.

Cancer Immunol Immunother. 2017 Sep;66(9):1123-1130. doi: 10.1007/s00262-017-2001-3. Epub 2017 Apr 20.

PMID:
28429069
15.

Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.

Bjoern J, Lyngaa R, Andersen R, Rosenkrantz LH, Hadrup SR, Donia M, Svane IM.

Oncotarget. 2017 Apr 18;8(16):27062-27074. doi: 10.18632/oncotarget.16003. Erratum in: Oncotarget. 2018 Nov 9;9(88):35870.

16.

Evolution of MHC-based technologies used for detection of antigen-responsive T cells.

Bentzen AK, Hadrup SR.

Cancer Immunol Immunother. 2017 May;66(5):657-666. doi: 10.1007/s00262-017-1971-5. Epub 2017 Mar 17. Review.

17.

Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes.

Bentzen AK, Marquard AM, Lyngaa R, Saini SK, Ramskov S, Donia M, Such L, Furness AJ, McGranahan N, Rosenthal R, Straten PT, Szallasi Z, Svane IM, Swanton C, Quezada SA, Jakobsen SN, Eklund AC, Hadrup SR.

Nat Biotechnol. 2016 Oct;34(10):1037-1045. doi: 10.1038/nbt.3662. Epub 2016 Aug 29.

PMID:
27571370
18.

Neoantigen landscape dynamics during human melanoma-T cell interactions.

Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS, Hadrup SR, van der Minne CE, Schotte R, Spits H, Haanen JB, Kapiteijn EH, Schumacher TN, van der Burg SH.

Nature. 2016 Aug 4;536(7614):91-5. Epub 2016 Jun 27.

PMID:
27350335
19.

Immune Mechanisms in Myelodysplastic Syndrome.

Glenthøj A, Ørskov AD, Hansen JW, Hadrup SR, O'Connell C, Grønbæk K.

Int J Mol Sci. 2016 Jun 15;17(6). pii: E944. doi: 10.3390/ijms17060944. Review.

20.

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.

McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, Watkins TB, Shafi S, Murugaesu N, Mitter R, Akarca AU, Linares J, Marafioti T, Henry JY, Van Allen EM, Miao D, Schilling B, Schadendorf D, Garraway LA, Makarov V, Rizvi NA, Snyder A, Hellmann MD, Merghoub T, Wolchok JD, Shukla SA, Wu CJ, Peggs KS, Chan TA, Hadrup SR, Quezada SA, Swanton C.

Science. 2016 Mar 25;351(6280):1463-9. doi: 10.1126/science.aaf1490. Epub 2016 Mar 3.

21.

Design and validation of conditional ligands for HLA-B*08:01, HLA-B*15:01, HLA-B*35:01, and HLA-B*44:05.

Frøsig TM, Yap J, Seremet T, Lyngaa R, Svane IM, Thor Straten P, Heemskerk MH, Grotenbreg GM, Hadrup SR.

Cytometry A. 2015 Oct;87(10):967-75. doi: 10.1002/cyto.a.22689. Epub 2015 Jun 1.

22.

Thinking outside the gate: single-cell assessments in multiple dimensions.

Kvistborg P, Gouttefangeas C, Aghaeepour N, Cazaly A, Chattopadhyay PK, Chan C, Eckl J, Finak G, Hadrup SR, Maecker HT, Maurer D, Mosmann T, Qiu P, Scheuermann RH, Welters MJ, Ferrari G, Brinkman RR, Britten CM.

Immunity. 2015 Apr 21;42(4):591-2. doi: 10.1016/j.immuni.2015.04.006. No abstract available.

23.

Broadening the repertoire of melanoma-associated T-cell epitopes.

Frøsig TM, Lyngaa R, Met Ö, Larsen SK, Donia M, Svane IM, Thor Straten P, Hadrup SR.

Cancer Immunol Immunother. 2015 May;64(5):609-20. doi: 10.1007/s00262-015-1664-x. Epub 2015 Feb 18.

24.

Comment on "5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity".

Frøsig TM, Hadrup SR.

Mediators Inflamm. 2015;2015:871641. doi: 10.1155/2015/871641. Epub 2015 Mar 8. No abstract available.

25.

Cryopreservation of MHC multimers: Recommendations for quality assurance in detection of antigen specific T cells.

Hadrup SR, Maurer D, Laske K, Frøsig TM, Andersen SR, Britten CM, van der Burg SH, Walter S, Gouttefangeas C.

Cytometry A. 2015 Jan;87(1):37-48. doi: 10.1002/cyto.a.22575. Epub 2014 Oct 8.

26.

"Immunotherapy of cancer: present status and future promise": Danish Cancer Society Symposium, Copenhagen, Denmark, 23rd-25th September 2013.

Donia M, Lyngaa R, Hadrup SR.

Cancer Immunol Immunother. 2014 Sep;63(9):985-9. doi: 10.1007/s00262-014-1585-0. Epub 2014 Jul 24. No abstract available.

27.

5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies.

Gang AO, Frøsig TM, Brimnes MK, Lyngaa R, Treppendahl MB, Grønbæk K, Dufva IH, Straten PT, Hadrup SR.

Blood Cancer J. 2014 Mar 28;4:e197. doi: 10.1038/bcj.2014.14.

28.

T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors.

Lyngaa R, Pedersen NW, Schrama D, Thrue CA, Ibrani D, Met O, Thor Straten P, Nghiem P, Becker JC, Hadrup SR.

Clin Cancer Res. 2014 Apr 1;20(7):1768-78. doi: 10.1158/1078-0432.CCR-13-2697. Epub 2014 Feb 13.

29.

High-throughput identification of antigen-specific TCRs by TCR gene capture.

Linnemann C, Heemskerk B, Kvistborg P, Kluin RJ, Bolotin DA, Chen X, Bresser K, Nieuwland M, Schotte R, Michels S, Gomez-Eerland R, Jahn L, Hombrink P, Legrand N, Shu CJ, Mamedov IZ, Velds A, Blank CU, Haanen JB, Turchaninova MA, Kerkhoven RM, Spits H, Hadrup SR, Heemskerk MH, Blankenstein T, Chudakov DM, Bendle GM, Schumacher TN.

Nat Med. 2013 Nov;19(11):1534-41. doi: 10.1038/nm.3359. Epub 2013 Oct 13.

PMID:
24121928
30.

High frequency of T cells specific for cryptic epitopes in melanoma patients.

Andersen RS, Andersen SR, Hjortsø MD, Lyngaa R, Idorn M, Køllgård TM, Met O, Thor Straten P, Hadrup SR.

Oncoimmunology. 2013 Jul 1;2(7):e25374.

31.

Hierarchical Bayesian mixture modelling for antigen-specific T-cell subtyping in combinatorially encoded flow cytometry studies.

Lin L, Chan C, Hadrup SR, Froesig TM, Wang Q, West M.

Stat Appl Genet Mol Biol. 2013 Jun;12(3):309-31. doi: 10.1515/sagmb-2012-0001.

32.

Discovering naturally processed antigenic determinants that confer protective T cell immunity.

Gilchuk P, Spencer CT, Conant SB, Hill T, Gray JJ, Niu X, Zheng M, Erickson JJ, Boyd KL, McAfee KJ, Oseroff C, Hadrup SR, Bennink JR, Hildebrand W, Edwards KM, Crowe JE Jr, Williams JV, Buus S, Sette A, Schumacher TN, Link AJ, Joyce S.

J Clin Invest. 2013 May;123(5):1976-87. doi: 10.1172/JCI67388. Epub 2013 Apr 1.

33.

Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients.

Iversen TZ, Brimnes MK, Nikolajsen K, Andersen RS, Hadrup SR, Andersen MH, Bastholt L, Svane IM.

Oncoimmunology. 2013 Feb 1;2(2):e23288.

34.

Toward next-generation cancer immunotherapy: 10th annual meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 23-25, 2012.

Kloke BP, Kutscher S, Rae R, Kvistborg P, Britten CM, Hadrup SR.

Cancer Immunol Immunother. 2013 May;62(5):975-81. doi: 10.1007/s00262-012-1386-2. Epub 2013 Jan 9. No abstract available.

PMID:
23299564
35.

Conditional ligands for Asian HLA variants facilitate the definition of CD8+ T-cell responses in acute and chronic viral diseases.

Chang CX, Tan AT, Or MY, Toh KY, Lim PY, Chia AS, Froesig TM, Nadua KD, Oh HL, Leong HN, Hadrup SR, Gehring AJ, Tan YJ, Bertoletti A, Grotenbreg GM.

Eur J Immunol. 2013 Apr;43(4):1109-20. doi: 10.1002/eji.201243088. Epub 2013 Feb 14.

36.
37.

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.

Ellebaek E, Iversen TZ, Junker N, Donia M, Engell-Noerregaard L, Met Ö, Hölmich LR, Andersen RS, Hadrup SR, Andersen MH, thor Straten P, Svane IM.

J Transl Med. 2012 Aug 21;10:169. doi: 10.1186/1479-5876-10-169.

38.

TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients.

Kvistborg P, Shu CJ, Heemskerk B, Fankhauser M, Thrue CA, Toebes M, van Rooij N, Linnemann C, van Buuren MM, Urbanus JH, Beltman JB, Thor Straten P, Li YF, Robbins PF, Besser MJ, Schachter J, Kenter GG, Dudley ME, Rosenberg SA, Haanen JB, Hadrup SR, Schumacher TN.

Oncoimmunology. 2012 Jul 1;1(4):409-418.

39.

Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers.

Andersen RS, Kvistborg P, Frøsig TM, Pedersen NW, Lyngaa R, Bakker AH, Shu CJ, Straten Pt, Schumacher TN, Hadrup SR.

Nat Protoc. 2012 Apr 12;7(5):891-902. doi: 10.1038/nprot.2012.037.

PMID:
22498709
40.

Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial.

Ellebaek E, Engell-Noerregaard L, Iversen TZ, Froesig TM, Munir S, Hadrup SR, Andersen MH, Svane IM.

Cancer Immunol Immunother. 2012 Oct;61(10):1791-804. Epub 2012 Mar 20.

PMID:
22426890
41.

Dissection of T-cell antigen specificity in human melanoma.

Andersen RS, Thrue CA, Junker N, Lyngaa R, Donia M, Ellebæk E, Svane IM, Schumacher TN, Thor Straten P, Hadrup SR.

Cancer Res. 2012 Apr 1;72(7):1642-50. doi: 10.1158/0008-5472.CAN-11-2614. Epub 2012 Feb 6.

42.

Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion.

Brimnes MK, Gang AO, Donia M, Thor Straten P, Svane IM, Hadrup SR.

Cancer Immunol Immunother. 2012 Aug;61(8):1221-31. doi: 10.1007/s00262-011-1199-8. Epub 2012 Jan 12.

PMID:
22237888
43.

High-throughput identification of potential minor histocompatibility antigens by MHC tetramer-based screening: feasibility and limitations.

Hombrink P, Hadrup SR, Bakker A, Kester MG, Falkenburg JH, von dem Borne PA, Schumacher TN, Heemskerk MH.

PLoS One. 2011;6(8):e22523. doi: 10.1371/journal.pone.0022523. Epub 2011 Aug 5.

44.

Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators.

Sørensen RB, Hadrup SR, Svane IM, Hjortsø MC, Thor Straten P, Andersen MH.

Blood. 2011 Feb 17;117(7):2200-10. doi: 10.1182/blood-2010-06-288498. Epub 2010 Nov 15.

45.

Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial.

Trepiakas R, Berntsen A, Hadrup SR, Bjørn J, Geertsen PF, Straten PT, Andersen MH, Pedersen AE, Soleimani A, Lorentzen T, Johansen JS, Svane IM.

Cytotherapy. 2010 Oct;12(6):721-34. doi: 10.3109/14653241003774045.

PMID:
20429791
46.

MHC-based detection of antigen-specific CD8+ T cell responses.

Hadrup SR, Schumacher TN.

Cancer Immunol Immunother. 2010 Sep;59(9):1425-33. doi: 10.1007/s00262-010-0824-2. Epub 2010 Feb 23. Review.

47.

The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase.

Sørensen RB, Berge-Hansen L, Junker N, Hansen CA, Hadrup SR, Schumacher TN, Svane IM, Becker JC, thor Straten P, Andersen MH.

PLoS One. 2009 Sep 7;4(9):e6910. doi: 10.1371/journal.pone.0006910.

48.

Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells.

Kwong GA, Radu CG, Hwang K, Shu CJ, Ma C, Koya RC, Comin-Anduix B, Hadrup SR, Bailey RC, Witte ON, Schumacher TN, Ribas A, Heath JR.

J Am Chem Soc. 2009 Jul 22;131(28):9695-703. doi: 10.1021/ja9006707.

49.

Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers.

Hadrup SR, Bakker AH, Shu CJ, Andersen RS, van Veluw J, Hombrink P, Castermans E, Thor Straten P, Blank C, Haanen JB, Heemskerk MH, Schumacher TN.

Nat Methods. 2009 Jul;6(7):520-6. doi: 10.1038/nmeth.1345. Epub 2009 Jun 21.

PMID:
19543285
50.

Longitudinal immune monitoring of patients receiving intratumoral injection of a MART-1 T-cell receptor-transduced cell line (C-Cure 709).

Køllgaard T, Duval L, Schmidt H, Kaltoft K, Seremet T, Andersen MH, Maase Hv, Straten Pt, Hadrup SR.

Cytotherapy. 2009;11(5):631-41. doi: 10.1080/14653240902923146.

PMID:
19530030

Supplemental Content

Loading ...
Support Center